Form 4: Guardant Health Director Myrtle Potter Reports RSU Vesting and Share Acquisition

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the acquisition of 68 shares of common stock on July 15, 2025, increasing her direct beneficial ownership to 18,222 shares.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), reported a transaction on July 15, 2025.
• The transaction involved the exercise or conversion of 68 Restricted Stock Units (RSUs) into 68 shares of Guardant Health Common Stock.
• The acquisition price for these shares was $0, indicating a vesting event.
• Following this transaction, Ms. Potter directly beneficially owns 18,222 shares of Guardant Health Common Stock.
• She also directly beneficially owns 206 Restricted Stock Units.
• The RSUs are part of an award that vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over a three-year period thereafter.

Sentiment

Score: 7

Explanation: The transaction is a routine RSU vesting, which is a neutral event in itself but reflects a director's continued equity ownership and alignment with the company's performance. It's not a sale, which would typically be viewed more negatively.

Positives

• A director is increasing their direct ownership of common stock through RSU vesting, which can be seen as a positive sign of continued alignment with shareholder interests.

Negatives

• NA

Risks

• NA

Future Outlook

The filing indicates ongoing vesting of restricted stock units for the reporting person, with the remaining 75% of the award vesting in substantially equal monthly installments over a three-year period from October 15, 2022.

Management Comments

• NA

Industry Context

This transaction is a routine insider equity compensation event, common across the biotechnology and healthcare sectors, reflecting standard executive and director compensation practices involving equity awards.

Comparison to Industry Standards

• The vesting of restricted stock units at a $0 exercise price is a standard practice for equity compensation in publicly traded companies, aligning director incentives with long-term shareholder value.
• This is comparable to similar RSU vesting schedules seen at companies like Illumina, Exact Sciences, or Pacific Biosciences, where equity awards are a significant component of executive and director compensation.

Stakeholder Impact

• Shareholders: The transaction increases a director's direct shareholding, potentially signaling confidence and aligning interests.
• Employees: This is a director's compensation event and does not directly impact general employees.

Next Steps

• Continued monthly vesting of the remaining 206 Restricted Stock Units held by Myrtle S. Potter.

Key Dates

Recommendation

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Stock Ownership, Beneficial Ownership, Equity Compensation